At Bayer, we are helping to drive medical progress through our focus on researching, developing, and marketing innovative medicines. Our near-term growth is driven by key products in cardiovascular therapy area, while our near- and mid-term growth will be further fueled by launch products in oncology, cardiovascular and cardiorenal areas and late-stage R&D pipeline candidates in cardiovascular therapy area. To safeguard long-term growth, we continue to invest in R&D in therapeutic areas with a substantial need for innovation. Moreover, we are expanding our efforts to access external innovation through research collaborations and in-licensing, capturing continued growth opportunities in biologics and novel technologies. Another key focus is on improving women’s health and strengthening their role in society by helping to promote gender equality and women’s economic participation. As part of this endeavor, we are leveraging our leading position in women’s health and are aiming to provide 100 million women in low- and middle-income countries with access to modern contraception by 2030. In addition, we remain committed to combating neglected tropical diseases and noncommunicable diseases.